 |
|
 |
|
|
 |
|||
       |
|||
|
|||
 |
|||
|
|||
Segment Results - 3rd Quarter Fiscal Year 2009
- TECHNE Corporation and Subsidiaries
- Hematology Division
- Biotechnology Division
- R&D Systems Europe (in £'s)
- R&D Systems Europe (in $'s)
- Corporate and Other
| Fiscal 2009 | Increase(Decrease) From Fiscal 2008 | ||||||||
| First Quarter | Second Quarter | Third Qurter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Qurter | YTD | |
Sales |
69,324 |
61,876 |
67,866 |
199,066 |
100% |
11,337 |
(266) |
(1,656) |
9,415 |
Cost of sales |
13,086 |
13,430 |
14,316 |
40,832 |
21% |
982 |
679 |
170 |
1,831 |
Gross margin |
56,238 |
48,446 |
53,550 |
158,234 |
79% |
10,355 |
(945) |
(1,826) |
7,584 |
Gross margin percentage |
81.1% |
78.3% |
78.9% |
79.5% |
|||||
SG&A expense |
8,840 |
9,703 |
7,061 |
25,604 |
13% |
750 |
(942) |
(1,933) |
(2,125) |
R&D expense |
5,910 |
5,846 |
5,809 |
17,565 |
9% |
729 |
284 |
(30) |
983 |
Amortization expense |
240 |
240 |
240 |
720 |
- |
(48) |
(42) |
(43) |
(133) |
Interest income |
(2,887) |
(2,205) |
(1,504) |
(6,596) |
(3%) |
111 |
1,047 |
1,651 |
2,809 |
Other non-operating ex., net |
1,187 |
712 |
1,103 |
3,002 |
1% |
618 |
139 |
680 |
1,437 |
13,290 |
14,296 |
12,709 |
40,295 |
20% |
2,160 |
486 |
325 |
2,971 |
|
Earnings before income taxes |
42,948 |
34,150 |
40,841 |
117,939 |
59% |
8,195 |
(1,431) |
(2,151) |
4,613 |
Income taxes |
14,355 |
10,528 |
13,200 |
38,083 |
19% |
2,674 |
(1,414) |
(202) |
1,058 |
28,593 |
23,622 |
27,641 |
79,856 |
40% |
5,521 |
(17) |
(1,949) |
3,555 |
|
Diluted earnings per share |
.74 |
.62 |
.74 |
2.10 |
|||||
Weighted average diluted shares outstanding |
38,747 |
37,992 |
37,499 |
38,085 |
|||||
Back to Top
| Fiscal 2009 | Increase(Decrease) From Fiscal 2008 | ||||||||
| First Quarter | Second Quarter | Third Qurter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Qurter | YTD | |
Sales |
4,246 |
4,260 |
4,434 |
12,940 |
100% |
589 |
288 |
228 |
1,105 |
Cost of sales |
2,369 |
2,405 |
2,325 |
7,099 |
55% |
108 |
129 |
(141) |
96 |
Gross margin |
1,877 |
1,855 |
2,109 |
5,841 |
45% |
481 |
159 |
369 |
1,009 |
Gross margin percentage |
44.2% |
43.5% |
47.6% |
45.1% |
|||||
SG&A expense |
436 |
398 |
310 |
1,144 |
9% |
(31) |
(89) |
(179) |
(299) |
R&D expense |
193 |
203 |
187 |
583 |
4% |
14 |
9 |
(12) |
11 |
Interest, net |
(102) |
(91) |
(80) |
(273) |
(2%) |
18 |
34 |
43 |
95 |
527 |
510 |
417 |
1,454 |
11% |
1 |
(46) |
(148) |
(193) |
|
Pretax result |
1,350 |
1,345 |
1,692 |
4,387 |
34% |
480 |
205 |
517 |
1,202 |
Back to Top
| Fiscal 2009 | Increase(Decrease) From Fiscal 2008 | ||||||||
| First Quarter | Second Quarter | Third Qurter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Qurter | YTD | |
Sales |
53,899 |
48,643 |
53,718 |
156,260 |
100% |
8,571 |
2,067 |
806 |
11,444 |
Intersegment sales |
(7,762) |
(8,311) |
(8,579) |
(24,652) |
|
(1,315) |
(878) |
(757) |
(2,950) |
46,137 |
40,332 |
45,139 |
131,608 |
7,256 |
1,189 |
49 |
8,494 |
||
|
|
|
|
|
|
|
|
|
|
Cost of sales |
10,247 |
11,090 |
11,080 |
32,417 |
21% |
1,250 |
1,478 |
371 |
3,099 |
Intersegment sales |
(7,461) |
(8,339) |
(8,494) |
(24,294) |
|
(1,287) |
(909) |
(739) |
(2,935) |
2,786 |
2,751 |
2,586 |
8,123 |
(37) |
569 |
(368) |
164 |
||
Gross margin |
43,351 |
37,581 |
42,553 |
123,485 |
79% |
7,293 |
620 |
417 |
8,330 |
Gross margin percentage |
81.0% |
77.2% |
79.4% |
79.3% |
|||||
SG&A expense |
5,141 |
5,418 |
4,262 |
14,821 |
9% |
517 |
(116) |
(995) |
(594) |
R&D expense |
5,717 |
5,643 |
5,622 |
16,982 |
11% |
715 |
275 |
(18) |
972 |
Amortization expense |
240 |
240 |
240 |
720 |
-- |
(48) |
(42) |
(43) |
(133) |
Interest, net |
(1,084) |
(970) |
(853) |
(2,907) |
(1%) |
173 |
339 |
432 |
944 |
Exchange loss/(gain) |
(2) |
1 |
1 |
-- |
-- |
(36) |
(11) |
6 |
(41) |
10,012 |
10,332 |
9,272 |
29,616 |
19% |
1,321 |
445 |
(618) |
1,148 |
|
Pretax result |
33,339 |
27,249 |
33,281 |
93,869 |
60% |
5,972 |
175 |
1,035 |
7,182 |
(1) Includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.
Back to Top
| Fiscal 2009 | Increase(Decrease) From Fiscal 2008 | ||||||||
| First Quarter | Second Quarter | Third Qurter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Qurter | YTD | |
Sales |
10,175 |
11,197 |
12,716 |
34,088 |
100% |
2,570 |
1,896 |
2,536 |
7,002 |
Cost of sales |
4,260 |
5,361 |
6,540 |
16,161 |
47% |
805 |
1,308 |
2,148 |
4,261 |
Gross margin |
5,915 |
5,836 |
6,176 |
17,927 |
53% |
1,765 |
588 |
388 |
2,741 |
Gross margin percentage |
58.1% |
52.1% |
48.6% |
52.6% |
|||||
SG&A expense |
1,224 |
1,364 |
1,191 |
3,779 |
11% |
110 |
88 |
28 |
226 |
Interest income |
(790) |
(583) |
(235) |
(1,608) |
(4%) |
(107) |
190 |
527 |
610 |
Exchange loss/(gain) |
260 |
(35) |
163 |
388 |
1% |
356 |
46 |
393 |
795 |
694 |
746 |
1,119 |
2,559 |
8% |
359 |
324 |
948 |
1,631 |
|
Pretax result |
5,221 |
5,090 |
5,057 |
15,368 |
45% |
1,406 |
264 |
(560) |
1,110 |
Back to Top
| Fiscal 2009 | Increase(Decrease) From Fiscal 2008 | ||||||||
| First Quarter | Second Quarter | Third Qurter | YTD | Percent Of Sales | First Quarter | Second Quarter | Third Qurter | YTD | |
Sales |
18,941 |
17,284 |
18,293 |
54,518 |
100% |
3,492 |
(1,743) |
(1,933) |
(184) |
Cost of sales |
7,931 |
8,274 |
9,405 |
25,610 |
47% |
911 |
(19) |
679 |
1,571 |
Gross margin |
11,010 |
9,010 |
8,888 |
28,908 |
53% |
2,581 |
(1,724) |
(2,612) |
(1,755) |
Gross margin percentage |
58.1% |
52.1% |
48.6% |
53.0% |
|||||
SG&A expense |
2,283 |
2,094 |
1,714 |
6,091 |
11% |
21 |
(505) |
(597) |
(1,081) |
Interest income |
(1,471) |
(906) |
(338) |
(2,715) |
(5%) |
(84) |
670 |
1,176 |
1,762 |
Exchange loss |
476 |
5 |
238 |
719 |
1% |
674 |
170 |
695 |
1,539 |
1,288 |
1,193 |
1,614 |
4,095 |
7% |
611 |
335 |
1,274 |
2,220 |
|
Pretax result |
9,722 |
7,817 |
7,274 |
24,813 |
46% |
1,970 |
(2,059) |
(3,886) |
(3,975) |
Back to Top
| Fiscal 2009 | Increase(Decrease) From Fiscal 2008 | |||||||
| First Quarter | Second Quarter | Third Qurter | YTD | First Quarter | Second Quarter | Third Qurter | YTD | |
Interest income |
230 |
238 |
233 |
701 |
(4) |
(4) |
-- |
(8) |
Rental income |
99 |
131 |
115 |
345 |
32 |
20 |
24 |
76 |
329 |
369 |
348 |
1,046 |
28 |
16 |
24 |
68 |
|
SG&A expense |
980 |
1,793 |
775 |
3,548 |
243 |
(232) |
(162) |
(151) |
Other-Building expenses |
553 |
551 |
573 |
1,677 |
9 |
(49) |
(60) |
(100) |
Other-Equity Investment losses |
259 |
286 |
406 |
951 |
3 |
49 |
63 |
115 |
1,792 |
2,630 |
1,754 |
6,176 |
255 |
(232) |
(159) |
(136) |
|
Pretax result |
(1,463) |
(2,261) |
(1,406) |
(5,130) |
(227) |
248 |
183 |
204 |
Back to Top
(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC and Nephromics, LLC.
|
Home -
Company News -
Financial Information -
About TECHNE -
Map/Directions -
Products -
Contact Us
TECHNE CORPORATION 614 McKinley Place N.E. Minneapolis, MN 55413-2610 Phone: (612)379-8854 Fax: (612)379-6580 e-mail: techinfo@techne-corp.com * Up to a 15 minute delay on Market Overview. Please consult your financial advisor for an up-to-minute quote. Quote provided by Barchart.com. |